Poly Medicure Ltd

Poly Medicure Earnings Call: Key Takeaways

Poly Medicure delivered strong FY26 performance with 12.3% consolidated revenue growth and significant gross margin expansion. Strategy focuses on high-end tech segments through Citieffe and PendraCare acquisitions.

Poly Medicure Q4 FY26 Results: Net Profit ₹65 Cr, Down 29.2% YoY

Poly Medicure Ltd reported revenue from operations of ₹534.5 Cr (+21.3% YoY) and net profit of ₹65 Cr (-29.2% YoY) for Q4 FY26.

Key figure

Net profit ₹65 Cr · -29.2% YoY

Poly Medicure Financial Results

Poly Medicure Limited reported audited financial results for FY2025-26 and recommended a Rs 3.5 dividend per share. The board also re-appointed internal auditors for the next year.

Value

₹3.50 Cr

Poly Medicure Employee Stock Options

Poly Medicure granted 17,500 stock options at ₹100 per share under its 2020 ESOP scheme. The options vest over four years, aligning employee and shareholder interests.

Value

₹0.18 Cr

Execution

Vesting over 4 years

Poly Medicure Board Meeting Date

Poly Medicure scheduled a board meeting on May 25, 2026. The board will consider audited financial results and a potential final dividend recommendation.

Poly Medicure Acquisition

Poly Medicure Limited's Brazilian subsidiary has acquired 100% equity in MEDYNEO COMERCIO DE PRODUTOS PARA SAUDE LTDA. The acquisition provides essential operating licenses for the commercialization, importation, and distribution of medical devices in Brazil, strengthening the company's South American market presence.

Poly Medicure Acquisition Worth ₹0.34 Cr

Poly Medicure Limited, through its subsidiary Polymed Brazil LTDA, acquired 100% equity in Brazil-based MEDYNEO for R$180,000 (approx. ₹0.34 Crore). The acquisition provides necessary licenses for medical device importation and commercialization in Brazil.

Value

₹0.34 Cr